Home | Meeting coverage | ASCO GU 2022

Bladder Cancer: Discussions

ASCO GU 2022

P. J. Goebell, M.-O. Grimm, J. Bellmunt, P. Grivas, S. Chowdhury

Role of PARPi in urothelial cancer

ATLANTIS, BAYOU, MEET-URO12

ASCO GU 2022

P. J. Goebell, M.-O. Grimm, J. Bellmunt, P. Grivas, S. Chowdhury

Neoadjuvant therapy in UTUC: Good options for selected...

ASCO GU 2022

P. J. Goebell, M.-O. Grimm, J. Bellmunt, P. Grivas, S. Chowdhury

ADC in bladder cancer: defining the future!

TROPHY-U-001, EV-103

Bladder Cancer: 100 Seconds

ASCO GU 2022

Tom Powles, MD

PARPi in urothelial cancer: DFS advantage for the DDR+,...

BAYOU, ATLANTIS

ASCO GU 2022

Petros Grivas, MD

Follow-up data confirm OS benefit across subgroups

JAVELIN Bladder 100

ASCO GU 2022

Neal Shore, MD

Ongoing immunotherapy innovation for mCRPC

KEYNOTE-365

ASCO GU 2022

Petros Grivas, MD

ADC shape the therapy landscape in urothelial cancer

TROPHY-U-001, DS8201

ASCO GU 2022

Marc-Oliver Grimm, MD

IO escalation results in improved response in met. TCC.

TITAN-TCC

ASCO GU 2022

Tom Powles, MD

Mature data confirm efficacy of maintenance avelumab as...

JAVELIN Bladder 100

ASCO GU 2022

Petros Grivas, MD

Patient selection for bladder preservation

ASCO GU 2022

Petros Grivas, MD

Not practice changing, but hypothesis generating.

ATLANTIS, BAYOU, MEET-URO12

ASCO GU 2022

Philipp Ivanyi, MD

HER2 ERBB2 – entering precision oncology

DS8201-A-U105; RC48-C014

ASCO GU 2022

Marc-Oliver Grimm, MD

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

CheckMate-274

ASCO GU 2022

Simon Chowdhury, MD

ADCs will be step-changing in urothelial cancers

DS8201-A-U105

ASCO GU 2022

Axel Merseburger, MD

Exciting data supports trimodality therapy

Prostate Cancer: Discussions

ASCO GU 2022

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

Enza beyond progression? Practice changing or not?

PRESIDE

ASCO GU 2022

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

Do we need testing? Which biomarkers are of relevance?

PROpel; MAGNITUDE

ASCO GU 2022

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

Theranostics – Presence and future: Vision, PSMAfore,...

VISION; PSMAfore; PSMAddition; TheraP

ASCO GU 2022

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

The future of genetic testing. Somatic vs. germline?...

ASCO GU 2022

A. Bjartell, N. Shore, A. Merseburger, M.-O. Grimm, G. Morgan; S. Chowdhury, E. Efstathiou

Triplet vs. doublet: Which patients should we consider?

ARASENS

Prostate Cancer: 100 Seconds

ASCO GU 2022

Eleni Efstathiou, MD

Is biomarker development taking a back seat in prostate...

ASCO GU 2022

Gil Morgan, MD

Should we use arbiraterone and olaparib as 1st line...

PROpel

ASCO GU 2022

Neal Shore, MD

Subgroup analyses confirm the importance of oral daily...

HERO

ASCO GU 2022

Anders Bjartell, MD

New therapies and molecular targets in prostate cancer

ASCO GU 2022

Gil Morgan, MD

Addition of darolutamide improves OS in met....

Arasens

ASCO GU 2022

Eleni Efstathiou, MD

Where do PROpel and Magnitude agree?

PROpel MAGNITUDE

ASCO GU 2022

Anders Bjartell, MD

PSMA and FDG PET as biomarkers for response to LuPSMA

TheraP ANZUP 1603

ASCO GU 2022

Axel Merseburger, MD

Is the dual hormone-backbone the future?

PRESIDE

ASCO GU 2022

Neal Shore, MD

The importance of conducting HCRA

ASCO GU 2022

Simon Chowdhury, MD

PSA response correlates with OS and benefits in QoL

SPARTAN & TITAN

ASCO GU 2022

Anders Bjartell, MD

DARO in triplet therapy for CRPC

ARASENS

ASCO GU 2022

Gil Morgan, MD

HRR testing: MAGNITUDE vs. PROpel

PROpel; Magnitude

ASCO GU 2022

Elena Efstathiou, MD

Is docetaxel still needed for hormone sensitive mCRPC?

ARASENS

ASCO GU 2022

Axel Merseburger, MD

PROpel & Magnitude: who wins the race?

MAGNITUDE, PROpel

ASCO GU 2022

Anders Bjartell, MD

PRESIDE indicates benefit of continuation ENZA + ADT

PRESIDE

ASCO GU 2022

Neal Shore, MD

The need for biomarker panels in biopsy decision making

MiCheck

ASCO GU 2022

Simon Chowdhury, MD

Exciting new compound for mCRPC

DS7300

ASCO GU 2022

Gil Morgan, MD

Should we use arbiraterone and niraparib as 1st line...

Magnitude

ASCO GU 2022

Anders Bjartell, MD

How to improve PSMA based radioligand therapy

ASCO GU 2022

Axel Merseburger, MD

Triplet-therapy as a novel treatment option

ARASENS

Renal Cell Carcinoma: Discussions

ACO GU 2022

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

Treatment options following adjuvant PD1 Therapy:...

TITAN-RCC, HCRN GU16-260

ASCO GU 2022

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

Adjuvant PD1 Therapy confirms significant benefit for...

Keynote-564

ASCO GU 2022

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

Thoughts on first line treatment options following ASCO...

CheckMate 9ER

ASCO GU 2022

T. Powles, H. Hammers, M.-O. Grimm, S. Chowdhury, P. Ivanyi

Neoadjuvant IO+TKI Treatment: We need more data on...

NeoAvAx

Renal Cell Carcinoma: 100 seconds

ASCO GU 2022

Tom Powles, MD

Consistent OS benefit confirmed. Consider overtreatment...

KEYNOTE-564

ASCO GU 2022

Hans Hammers, MD

Neoadjuvant avelumab/axitinib - NeoAvAx

NeoAvAx

ASCO GU 2022

Philipp Ivanyi, MD

Data gap in 2nd line RCC: what’s new?

CaboCHECK; CABOSEQ

ASCO GU 2022

Sumanta Kumar Pal, MD

Update in neoadjuvant therapy for kidney cancer

NeoAvAx

ASCO GU 2022

Hans Hammers, MD

Nivo montoherapy followed by Nivi-Ipi resuce

HCRN GU16-260

ASCO GU 2022

Philipp Ivanyi, MD

CheckMate final OS Follow Up and health related QoL

CheckMate 9ER; CheckMate 214

ASCO GU 2022

Sumanta Kumar Pal, MD

Update in adjuvant therapy for kidney cancer

KEYNOTE 564

ASCO GU 2022

Hans Hammers, MD

Adjuvant Pembroluzimab update in kidney cancer

KEYNOTE-564

ASCO GU 2022

Philipp Ivanyi, MD

Microbioma modification and checkpoint inhibition

ASCO GU 2022

Sumanta Kumar Pal, MD

Frontline treatment of metastatic kidney cancer

CheckMate9ER; CABOSEQ